-+ 0.00%
-+ 0.00%
-+ 0.00%

Canaccord Genuity Maintains Buy on ATAI Life Sciences, Raises Price Target to $12

Benzinga·07/02/2025 15:25:28
Listen to the news
Canaccord Genuity analyst Sumant Kulkarni maintains ATAI Life Sciences (NASDAQ:ATAI) with a Buy and raises the price target from $11 to $12.